Annual direct and indirect health care costs of chronic idiopathic urticaria: A cost analysis of 50 nonimmunosuppressed patients

Laura K. DeLong, Steven D. Culler, Sarbjit S Saini, Lisa A. Beck, Suephy C. Chen

Research output: Contribution to journalArticle

Abstract

Objective: To estimate annual direct and indirect health care costs in patients with chronic idiopathic urticaria (CIU) managed with conventional therapies. Design: A cost analysis consisting of a survey-guided and retrospective medical record review of direct and indirect health care costs from a societal perspective in patients with CIU. Setting: The Johns Hopkins University allergy and dermatology ambulatory clinics. Participants: Fifty adults with active CIU were recruited in sequential order. Individuals who were taking corticosteroids or other immunosuppressants in the month before enrollment were excluded from the study. Main Outcome Measures: We estimated direct health care costs, which included laboratory, medication, outpatient visit, and emergency department and hospital visit costs. We also estimated indirect costs, which included earnings lost owing to travel to outpatient visits and absences from work owing to CIU-related illness. Results: Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5% ($1280) of the total annual cost. Indirect costs accounted for 15.7% ($322) of the total costs. Conclusions: High medication costs, followed by total indirect costs, result in the largest economic burden among patients with CIU. High medication costs may place low-income patients at risk for suboptimal treatment and increased burden due to poorly controlled disease. Our estimated total health care costs for CIU are comparable to those of other skin diseases such as vitiligo and bullous disease.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalArchives of Dermatology
Volume144
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Urticaria
Health Care Costs
Costs and Cost Analysis
Outpatients
Vitiligo
Cost of Illness
Hospital Costs
Immunosuppressive Agents
Dermatology
Skin Diseases
Medical Records
Hospital Emergency Service
Adrenal Cortex Hormones
Hypersensitivity
Economics
Outcome Assessment (Health Care)
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Annual direct and indirect health care costs of chronic idiopathic urticaria : A cost analysis of 50 nonimmunosuppressed patients. / DeLong, Laura K.; Culler, Steven D.; Saini, Sarbjit S; Beck, Lisa A.; Chen, Suephy C.

In: Archives of Dermatology, Vol. 144, No. 1, 01.2008, p. 35-39.

Research output: Contribution to journalArticle

DeLong, Laura K. ; Culler, Steven D. ; Saini, Sarbjit S ; Beck, Lisa A. ; Chen, Suephy C. / Annual direct and indirect health care costs of chronic idiopathic urticaria : A cost analysis of 50 nonimmunosuppressed patients. In: Archives of Dermatology. 2008 ; Vol. 144, No. 1. pp. 35-39.
@article{ef9959f36fd44f7cad9458ace4d88970,
title = "Annual direct and indirect health care costs of chronic idiopathic urticaria: A cost analysis of 50 nonimmunosuppressed patients",
abstract = "Objective: To estimate annual direct and indirect health care costs in patients with chronic idiopathic urticaria (CIU) managed with conventional therapies. Design: A cost analysis consisting of a survey-guided and retrospective medical record review of direct and indirect health care costs from a societal perspective in patients with CIU. Setting: The Johns Hopkins University allergy and dermatology ambulatory clinics. Participants: Fifty adults with active CIU were recruited in sequential order. Individuals who were taking corticosteroids or other immunosuppressants in the month before enrollment were excluded from the study. Main Outcome Measures: We estimated direct health care costs, which included laboratory, medication, outpatient visit, and emergency department and hospital visit costs. We also estimated indirect costs, which included earnings lost owing to travel to outpatient visits and absences from work owing to CIU-related illness. Results: Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5{\%} ($1280) of the total annual cost. Indirect costs accounted for 15.7{\%} ($322) of the total costs. Conclusions: High medication costs, followed by total indirect costs, result in the largest economic burden among patients with CIU. High medication costs may place low-income patients at risk for suboptimal treatment and increased burden due to poorly controlled disease. Our estimated total health care costs for CIU are comparable to those of other skin diseases such as vitiligo and bullous disease.",
author = "DeLong, {Laura K.} and Culler, {Steven D.} and Saini, {Sarbjit S} and Beck, {Lisa A.} and Chen, {Suephy C.}",
year = "2008",
month = "1",
doi = "10.1001/archdermatol.2007.5",
language = "English (US)",
volume = "144",
pages = "35--39",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Annual direct and indirect health care costs of chronic idiopathic urticaria

T2 - A cost analysis of 50 nonimmunosuppressed patients

AU - DeLong, Laura K.

AU - Culler, Steven D.

AU - Saini, Sarbjit S

AU - Beck, Lisa A.

AU - Chen, Suephy C.

PY - 2008/1

Y1 - 2008/1

N2 - Objective: To estimate annual direct and indirect health care costs in patients with chronic idiopathic urticaria (CIU) managed with conventional therapies. Design: A cost analysis consisting of a survey-guided and retrospective medical record review of direct and indirect health care costs from a societal perspective in patients with CIU. Setting: The Johns Hopkins University allergy and dermatology ambulatory clinics. Participants: Fifty adults with active CIU were recruited in sequential order. Individuals who were taking corticosteroids or other immunosuppressants in the month before enrollment were excluded from the study. Main Outcome Measures: We estimated direct health care costs, which included laboratory, medication, outpatient visit, and emergency department and hospital visit costs. We also estimated indirect costs, which included earnings lost owing to travel to outpatient visits and absences from work owing to CIU-related illness. Results: Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5% ($1280) of the total annual cost. Indirect costs accounted for 15.7% ($322) of the total costs. Conclusions: High medication costs, followed by total indirect costs, result in the largest economic burden among patients with CIU. High medication costs may place low-income patients at risk for suboptimal treatment and increased burden due to poorly controlled disease. Our estimated total health care costs for CIU are comparable to those of other skin diseases such as vitiligo and bullous disease.

AB - Objective: To estimate annual direct and indirect health care costs in patients with chronic idiopathic urticaria (CIU) managed with conventional therapies. Design: A cost analysis consisting of a survey-guided and retrospective medical record review of direct and indirect health care costs from a societal perspective in patients with CIU. Setting: The Johns Hopkins University allergy and dermatology ambulatory clinics. Participants: Fifty adults with active CIU were recruited in sequential order. Individuals who were taking corticosteroids or other immunosuppressants in the month before enrollment were excluded from the study. Main Outcome Measures: We estimated direct health care costs, which included laboratory, medication, outpatient visit, and emergency department and hospital visit costs. We also estimated indirect costs, which included earnings lost owing to travel to outpatient visits and absences from work owing to CIU-related illness. Results: Patients with CIU consumed a mean (SD) of $2047 ($1483) annually. Because CIU is primarily an outpatient disease, medication costs alone accounted for 62.5% ($1280) of the total annual cost. Indirect costs accounted for 15.7% ($322) of the total costs. Conclusions: High medication costs, followed by total indirect costs, result in the largest economic burden among patients with CIU. High medication costs may place low-income patients at risk for suboptimal treatment and increased burden due to poorly controlled disease. Our estimated total health care costs for CIU are comparable to those of other skin diseases such as vitiligo and bullous disease.

UR - http://www.scopus.com/inward/record.url?scp=38549141969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549141969&partnerID=8YFLogxK

U2 - 10.1001/archdermatol.2007.5

DO - 10.1001/archdermatol.2007.5

M3 - Article

C2 - 18209166

AN - SCOPUS:38549141969

VL - 144

SP - 35

EP - 39

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 1

ER -